Levothyroxine Is No More For Lannett: Here’s How The Company Aims To Replace It

 
• By Dean Rudge
  
ManOnCliff
Lannett is attempting to bridge the gap left by Amneal snapping up distribution rights to levothyroxine • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business